Neena Bitritto-Garg joins Analyst Thursdays and talks Prothena, Sarepta, Acadia, Compass Pathways, Neumora, Sage, and Amylyx.

Salim Syed discusses this morning’s FOREST-HCM update, Gilead’s Trodelvy news, CRISPR’s allo CAR-T pivot, and more.

Tim Opler discusses the M&A environment, IPO windown, PIPE and crossover financings, and more.

Cantor Fitzgerald biotech analyst Eric Schmidt talks about themes he thinks will work in 2024, tracking important launches, and technologies

Head of Healthcare & Life Sciences Capital Markets Johanna Grossman describes the assets that NYSE has available for biotech companies that

Michael Yee shares takeaways from last week's conference in San Francisco and highlights his top names to watch.

Patrick Nosker gives his take on today's conference news and highlights the science behind some of his firm's top holdings.

Noubar Afeyan hits on themes like partnering with pharma in earlier stages, AI, and the globalization of biotech.

Brian Skorney comments on the Ambrx and Harpoon acquisitions, the year ahead in biotech, and his top picks Biogen, Neurocrine, and Biohaven.

Stifel's Benjamin Burnett gives his take on biotech and discusses Iovance, Cabaletta, Arcellx, Revolution, Fate, CRISPR, and Disc.

John Maraganore shares his thoughts about biotech's big achievements in 2023 and what to watch in 2024.

Ethan Perlstein describes the past and present of his rare diseases-focused company Perlara

Chris Garabedian's thoughts on the IPO market, products vs platforms, and more discipline and prioritization in biotech.

Sri Kosuri describes how Octant is using advances in biology, chemistry, multiplexing, and computing to create its platform.

Jory Bell and Nate Chang describe Playground Global's philosophy of investing in life sciences and assisting entrepreneurs.

Liisa Bayko talks about yesterdays pain data and also recent news from Alnylam, Altimmune, Caribou Biosciences, Insmed, and AN2 Therapeutics

The UC Berkeley professor and Innovative Genomics Institute director talks about the diseases that might be treated with gene editing.

Jacob Plieth shares his thoughts on MorphoSys, Syndax, Poseida, Arcellx, Autolus, Cogent, Dizal, and more.

Dr. Maus comments on CD19 lupus data, the recent FDA note on malignancies, and the work her lab is doing for brain and heme cancers.

Madeleine Armstrong shares her thoughts on CAR-T data in lupus, the menin inhibitor class, BCMA CAR-T, and Regeneron's bi-specifics.